Cidara Therapeutics (CDTX) CMO reports charitable gift of 450 shares

Rhea-AI Filing Summary

Cidara Therapeutics, Inc. reported an insider stock transfer by its Chief Medical Officer on a Form 4. On 12/29/2025, the officer made a bona fide gift of 450 shares of common stock to a donor-advised fund for charitable purposes, with no beneficial ownership or control retained over the donated shares. Following this transaction, the officer beneficially owns 20,886 shares of Cidara common stock, which includes 50 shares acquired through the company’s Employee Stock Purchase Plan on December 18, 2025.

Insider Trade Summary

Net Seller: 450 shares

Net Sell 1 txn

Insider Davarpanah Nicole Negar

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Gift	Common Stock	450	$0.00	$0.00

Holdings After Transaction: Common Stock — 20,886 shares (Direct)

Footnotes (2)

1. F1. This transaction reflects a bona fide gift of the Issuer's stock to a donor-advised fund (DAF) for charitable purposes. The Reporting Person retains no beneficial ownership or control over the donated securities following the contribution.
2. F2. Includes 50 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (ESPP) on December 18, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 12/29/2025 - 06:04 PM Learn about SEC filing dates

FAQ

What insider transaction did Cidara Therapeutics (CDTX) report in this Form 4?

The Chief Medical Officer of Cidara Therapeutics, Inc. reported a bona fide gift of 450 shares of common stock on 12/29/2025 to a donor-advised fund for charitable purposes.

How many Cidara Therapeutics (CDTX) shares did the insider gift and to whom?

The reporting person gifted 450 shares of Cidara common stock to a donor-advised fund (DAF) established for charitable purposes and retains no beneficial ownership or control over those shares.

How many Cidara Therapeutics (CDTX) shares does the insider own after this transaction?

After the reported gift, the Chief Medical Officer beneficially owns 20,886 shares of Cidara Therapeutics common stock.

Does the insider still control the Cidara (CDTX) shares that were donated?

No. The filing states that the reporting person retains no beneficial ownership or control over the 450 donated shares following the contribution to the donor-advised fund.

What role does the reporting person hold at Cidara Therapeutics (CDTX)?

The reporting person is an officer of Cidara Therapeutics, serving as the company’s Chief Medical Officer.

Are any of the insider’s remaining Cidara (CDTX) shares from an employee stock plan?

Yes. The 20,886 shares beneficially owned after the transaction include 50 shares acquired under Cidara’s Employee Stock Purchase Plan on December 18, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davarpanah Nicole Negar

(Last) (First) (Middle)

6310 NANCY RIDGE DRIVE

SUITE 101

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cidara Therapeutics, Inc. [ CDTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/29/2025		G(1)		450	D	$0	20,886(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction reflects a bona fide gift of the Issuer's stock to a donor-advised fund (DAF) for charitable purposes. The Reporting Person retains no beneficial ownership or control over the donated securities following the contribution.

2. Includes 50 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (ESPP) on December 18, 2025.

Remarks:

	/s/ Shane Ward, Attorney-in-Fact	12/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.